33results about How to "Increase telomerase activity" patented technology

Compounds and compositions for the transient expression of exogenous telomerase activity in a cell are provided. The compounds and compositions, which relate to a ribonucleic acid coding for a telomerase reverse transcriptase, are useful in the extension of telomeres in cells needing such treatment. Such cells include, for example, cells that contain shortened telomeres and cells from subjects that may benefit from telomere extension, for example subjects that suffer from, or are at risk of suffering from, age-related or other illnesses. Also provided are methods of extending telomeres through the administration of the provided compounds and compositions to animal cells, either in vitro or in vivo, and kits including the compounds or compositions and instructions for use.

Formulations containing plant extracts, in particular Astragalus extracts, and their use in inducing telomerase activity in cells, are described. Such compositions include pharmaceutical, including topical, and nutraceutical formulations. The methods and compositions are useful for treating diseases subject to treatment by an increase in telomerase activity in selected cells, such as, for example, HIV infection, various degenerative diseases, and acute or chronic skin ailments. They are also useful for enhancing replicative capacity of cells in culture, as in ex vivo cell therapy and proliferation of stem cells. Also described are cosmetic formulations of such extracts for conditioning the skin.

The present disclosure describes mammalian pluripotent embryonic-like stem cells (ELSCs) isolated from corneal limbal tissue, a non-embryonic tissue. The ELSCs of the present disclosure are capable of proliferating in an in vitro culture, maintain the potential to differentiate into cells of endoderm, mesoderm, and ectoderm lineage in culture, and are capable of forming embryoid-like bodies when placed in suspension culture. Thus, these cells possess multi-lineage differentiation potential and self-renewing capability. ELSCs may be a promising therapeutic tool, and may provide new therapeutic alternatives for various diseases, conditions, and injuries.

Methods are disclosed for generating HLA homozygous parthenogenetic human stem cell (hpSC-Hhom) lines from both HLA homozygous and HLA heterozygous donors. These hpSC-Hhom lines demonstrate typical human embryonic stem cell morphology, expressing appropriate stem cell markers and possessing high levels of alkaline phosphatase and telomerase activity. Additionally, injection of these cell lines into immunodeficient animals leads to teratoma formation. Furthermore, in the case of HLA heterozygous donors, the hpSC-Hhom lines inherit the haplotype from only one of the donor's parents. SNP data analysis suggests that hpSC-Hhom lines derived from HLA heterozygous oocyte donors are homozygous throughout the genome as assessed by single-nucleotide polymorphism (SNP) analysis. The protocol as disclosed minimizes the use of animal-derived components, which makes the stem cells more practical for clinical application.

The invention relates to a mesenchymal stem cell membrane, and concretely relates to a vitamin C induced mesenchymal stem cell membrane and a preparation method thereof. The preparation method which is simple, fast, and harmless has very important and far-reaching meanings on the tissue regeneration of the mesenchymal stem cell membrane in application fields of the cell substitution treatment and regeneration medical science, tissue engineering science and the like. The vitamin C induced mesenchymal stem cell membrane has a wide application prospect with continuous exploration and research and further advanced understanding of the mesenchymal stem cell membrane.

The present invention provides a method for enhancing the immune function of a memory T cell which comprises the step of coinhibting signalling via an inhibitory receptor which regulates T cell exhaustion and via the p38 MAP kinase signalling pathway in the T cell, and a method for treating and/or preventing an immune condition in a subject, which comprises the step of enhancing the immune function of a memory T cell in the subject by such a method. There is also provided a pharmaceutical composition or kit comprising an agent capable of inhibiting signalling via an inhibitory receptor which regulates T cell exhaustion, such as PD-1, and an agent capable of inhibiting the p38 MAP kinase signalling pathway.

In vitro methods are disclosed that rely on a novel phenomenon of secondary sprouting by cultured endothelial precursor cells, after angiogenic-like tube formation and collapse have occurred on a basement membrane matrix. Particularly disclosed is an in vitro method of isolating and expanding, from a mixed population of mammalian cells originating from a tissue sample, a cellular population enriched for endothelial sprout cells, including cells having one or more physiological and/or immunological features of endothelial precursor cells. Also disclosed is an in vitro method for a screening a substance for potential proangiogenic or antiangiogenic activity.

The invention relates to a cell line of precursor of forebrain nerve of a telomerase immortalization human embryo and an establishing method and application thereof; the cell line is preserved in China culture collection and management committee general biology center in 21st February 2008, with the collection number of CGMCC No.2372. The cell line of the invention is named as hSN12W-TERT; the cell line expresses growth factor receptor of human nerves and green fluorescent protein, has high activity of telomerase, double core type than normal human, continuous passage culture in vitro of 36 months with 45th generation at the present and population doubling of 100 to 200 times and has the property of contact inhibition and density inhibition; the neuron which is formed by differentiation of the cell line has the property of electrophysiology; the cell line can be differentiated into Gamma-aminobutyric acid (GABA) cholinergic neuron under the induction of bone marphogenic protein 2(BMP2).

The invention discloses a biological preparation containing liver stem cells. The biological preparation contains the following raw materials in parts by weight: 5ml-7ml of the liver stem cells, 2ml-4ml of peripheral blood stem cells, 3ml-5ml of albumin, 2g-4g of glucose, 2ml-3ml of 50% ethanol, 1g-1.2g of vitamin A and 100ml-120ml of a solvent. The solvent is a 0.9% sodium chloride; stem cells are primitive cells for forming each tissues and organs of mammals, cell nucleuses are mostly euchromatins and have relatively high telomerase activity, the stem cells can be divided into embryonic stemcells and adult stem cells, and the liver stem cells, the peripheral blood stem cells and the albumin are combined to be prepared into a stem cell biological preparation, so that the tissue regeneration of injured parts of livers can be effectively promoted, and a relatively good liver injury treatment effect can be achieved; and a preparation process is simple, and a water-bath heating manner isadopted, so that the water temperature can be controlled, the temperature environment of the preparation is guaranteed, the biological preparation has relatively stable performance, and the activityof the stem cells is guaranteed.

The invention belongs to the technical field of cosmetics, and particularly relates to an anti-aging skin care mask and a preparation process thereof. The anti-aging skin care mask comprises mask paper and mask liquid, the mask liquid is prepared from the following raw materials in parts by weight: 15 to 17 parts of cycloastragenol, 10 to 15 parts of a honeysuckle flower extracting solution, 10 to 13 parts of a white tea extracting solution, 6 to 10 parts of a saccharomycetes lysate extract, 3 to 6 parts of retinol, 5 to 15 parts of collagen, 3 to 6 parts of a humectant, 0.5 to 1 part of a preservative, 1 to 3 parts of an emulsifier, 5 to 10 parts of nicotinamide, 35 to 90 parts of water, 20 to 35 parts of panthenol, 15 to 30 parts of butanediol and 2 to 3 parts of carbomer. 1-2 parts of a dispersing agent; 0.5-1 part of disodium EDTA (Ethylene Diamine Tetraacetic Acid); the relative molecular mass of cycloastragenol is relatively small, so that the cycloastragenol has better fat solubility compared with astragaloside, and the cycloastragenol is easier to penetrate through cell membranes to be absorbed by organisms; moreover, cycloastragenol can improve the activity of telomerase, so that the multiplication capacity of CD3 and CD8T cells is improved, and the effect of delaying senescence can be achieved.

The invention relates to rat induced multipotent stem cells and a preparation method thereof. The preparation method for the rat induced multipotent stem cells comprises the following steps: A) constructing a lentiviral vector carrying a transcription factor, wherein the transcription factor may be Oct4, Sox2, c-Myc, Klf4, Lin28 or Nanog; and B) infecting rat adult cells by the lentiviral vector obtained in the step A) in a combination way, selecting the infected adult cells of which the shapes are similar to those of embryonic stem cells for cloning and continuous cell culture, and screening the cells which are in accordance with the characteristics of the embryonic stem cells for cloning to obtain rat iPS cells. The rat induced multipotent stem cells and the preparation method thereof contribute to establishing most suitable culturing conditions and a most suitable culturing method for the cell lines of rat ES cells; the rat iPS cells are good vectors for rat gene targeting; and the rat iPS cells contribute to disclosing various gene functions of a rat and complex development events.

A nutritional composition and method is provided in which telomerase expression can be safely activated in living cells. The nutritional composition can induce TERT mRNA or h-TERT mRNA and telomerase in vitro and in vivo while at the same time inhibiting potential side effects, helping to prevent certain types of cancer, and slowing the growth of any cancer cells that may exist in vivo. The method entails exposing cells to L-carnosine concentrations in the range of 51-100 mM or to a combination of L-carnosine and L-fucose in which the concentration of L-carnosine is 30-100 mM and the concentration of L-fucose is in the range from 0.1 micromolar to 100 mM.

The present invention provides a method for inhibiting the activation of telomerase and an agent for inhibiting the activation of telomerase, a method for inhibiting telomerase activity and an agent for inhibiting telomerase activity, a method for preventing and/or a method for treating a cancer disease, an agent for preventing and/or an agent for treating a cancer disease, all of which comprises inhibiting the binding of MAPKAPK3 to TERT that is a catalytic subunit of telomerase or inhibiting the phosphorylation of TERT by active MAPKAPK3; a method of identifying a compound that inhibits the binding of MAPKAPK3 to TERT or a compound that inhibits the phosphorylation of TERT by active MAPKAPK3; and a reagent kit.

The invention discloses a pulsatilla saponin composition. The pulsatilla saponin composition comprises pulsatilla saponin B4 and pulsatilla saponin B5 in a weight ratio of (1-81): 9. The invention further discloses a food or a medicine containing the pulsatilla saponin composition and application of the food or the medicine. A mouse aging model is prepared by using D-galactose (D-gal) subcutaneous injection, the anti-aging effect and possible mechanism of the pulsatilla saponin B4 + B5 extract are discussed, and a theoretical basis and an experimental basis are provided for subsequent prevention and treatment of aging and related diseases by the pulsatilla saponin.

Provided herein are ophthalmic formulations and eye drops that contain a telomerase activator as the active agent to increase telomerase activity. Also provided are methods for reducing the incidence of age-related eye conditions or for increasing viability of cells in the corneal tissue by administering or contacting the ophthalmic formulation to one or both eyes in a subject.